Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Gilead’s Livdelzi® Shows Sustained Efficacy in PBC, Reducing ALP, Relieving Itch, and Potentially Slowing Disease Progression

in those at highest risk. This reinforces our belief in Livdelzi’s treatment profile and its potential to help transform care for people living with PBC. At Gilead, we remain focused on delivering innovation that drives long-term impact for...

PRM Pharma Launches HemiClor® 12.5 mg, the First FDA-Approved Low-Dose Chlorthalidone Tablet for Hypertension

the nationwide availability of HemiClor® (chlorthalidone) 12.5 mg tablets, the first and only FDA-approved 12.5 mg formulation of chlorthalidone for the treatment of hypertension in adults. This milestone comes as the newly released 2025 AHA/ACC...

Leukogene Therapeutics’ M2T-CD33 (LTI-214) has received Orphan Drug Designation from the U.S. FDA for the treatment of Acute Myeloid Leukemia

that are both potent and safer for patients. This designation represents an important step toward our goal of transforming the treatment paradigm for AML.” Nathan Dolloff, PhD, Founder and CSO of Leukogene stated, “This is an important step forward...

LIfT BioSciences will present preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at the 40th Society for Immunotherapy of Cancer

of LIfT BioSciences, commented: “Being selected to present our latest data underscores growing recognition of our IMAN platform’s potential to transform immuno-oncology. Our findings highlight how our first-in-class IMANs can restore innate immune...

Data on BIMZELX® (bimekizumab-bkzx) in Hidradenitis Suppurativa Showed Sustained Improvements in Pain and Draining Tunnel Resolution for Three Years

a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately...

Phase 2 Data of GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity, Published in 'Vaccine

agent as the aerosolized anthrax spores can cause fatal respiratory infections. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over...

Serenity Mental Health Centers: Where to Get TMS Therapy in Colorado Springs

Centers Serenity Mental Health Centers is a leading provider of comprehensive mental health services, dedicated to transforming the lives of patients through compassionate, innovative, and evidence-based care. With 35 locations across the country,...

Merz Aesthetics® Introduces New BELOTERO® Syringe, Offering Greater Precision, Comfort, and Ease of Use.

With a patent-protected design developed exclusively for BELOTERO®, the new premium syringe, with the same trusted formula, stands out in the global marketplace with several key improvements, such as: Ergonomic Design: The redesigned syringe offers...

Samsung Epis Holdings, Newly Established, to Drive Growth for Samsung Bioepis and Its New Subsidiary

growth strategy designed to ensure efficient and effective resources while reinforcing the business strategies and platforms for the two subsidiaries. The New Subsidiary Company The new subsidiary company under Samsung Epis Holdings will develop...

Starting January 2026, Samsung Bioepis will commercialize BYOOVIZ® (ranibizumab) in Europe

of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: www.samsungbioepis.com

Fresenius Kabi’s biosimilars Conexxence® and Bomyntra® (denosumab-bnht) receive interchangeable designation from the FDA

Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. For more information, please visit www.fresenius-kabi.com/

During FII Week in Riyadh, Rubedo Life Sciences and SVAX announce a strategic partnership

targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role...

Real-world data presented at TCT 2025 demonstrates that the EggNest™ Complete Radiation Protection System significantly reduces radiation exposure for the entire cath lab

case. For context, the annual occupational exposure limit in the U.S. is 5,000 mRem—meaning an operator would need to perform over 31,000 cases before nearing that limit. With the typical interventionalist performing 300–500 cases annually, this...

CollPlant expands its distribution capabilities for rhCollagen in the United States and Canada

dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information please, visit http://www.collplant.com.

Baird Medical’s MWA system has achieved successful Medicare reimbursement at a prominent New York practice

operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, please visit www.merck.com

Prestigious Journal of Hematology & Oncology Accepts HanchorBio’s Novel CD47-SIRPα Therapeutic, HCB101, for Publication

highlights both the scientific importance of ongoing advancements and the journal's role as a leading international platform for preclinical and translational research on anti-CD47 therapies. "Publication in the Journal of Hematology & Oncology...

Mexico’s First Pharmaceutical Company, IFA Celtics, Deploys ForgeStop's NFC Anti-Counterfeit Tech

medicine authentication and among the first globally to deploy the technology at commercial scale. Using ForgeStop’s platform, encrypted EM Microelectronic NFC labels are embedded into millions of drug packs, giving patients, pharmacists, and...

Alcami to expand lab services at Durham, NC facility to meet rising biologics demand

Alcami's private equity ownership includes GHO Capital, The Vistria Group, and Ampersand Capital Partners. For more information, please visit https://www.alcami.com.

ADARx doses first patient in Phase 3 STOP-HAE trial; ADX-324 receives orphan drug designation for hereditary angioedema

About ADARx Pharmaceuticals ADARx Pharmaceuticals is a late-stage clinical biotechnology company dedicated to transforming cutting-edge science into next-generation RNA medicines across a broad range of therapeutic areas. We have developed...

To drive global expansion of digital chemistry and discovery, Chemify raises over $50 million in an oversubscribed Series B round

advanced laboratory for molecular design and synthesis. At its core, the Chemifarm integrates Chemify’s Chemputation platform, an extensible programming language, advanced robotics, and the world’s largest curated library of validated reactions....